Our aim was to utilize high-depth targeted regional sequencing (TRS) technology to detect more myeloid-cancer-related mutations, combined with clinical data, to estimate the prognosis of adults with CN-AML harboring NPM1 mutations. The gene discussed is NPM1; the disease is cancer.